Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
editorial
. 2010 Apr;7(2):149–152. doi: 10.1016/j.nurt.2010.03.007

Headache

Peter J Goadsby 1,✉
PMCID: PMC5084094  PMID: 20430312

The content is available as a PDF (57.7 KB).

References

  • 1.Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57:418–420. doi: 10.1001/archneur.57.3.418. [DOI] [PubMed] [Google Scholar]
  • 2.Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–645. doi: 10.1046/j.1526-4610.2001.041007638.x. [DOI] [PubMed] [Google Scholar]
  • 3.Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc. 2003;290:2443–2454. doi: 10.1001/jama.290.18.2443. [DOI] [PubMed] [Google Scholar]
  • 4.Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. New Engl J Med. 2002;346:257–270. doi: 10.1056/NEJMra010917. [DOI] [PubMed] [Google Scholar]
  • 5.Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62:509–525. doi: 10.1016/S0301-0082(00)00010-1. [DOI] [PubMed] [Google Scholar]
  • 6.Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675. doi: 10.1016/S0140-6736(01)06711-3. [DOI] [PubMed] [Google Scholar]
  • 7.Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44:414–425. doi: 10.1111/j.1526-4610.2004.04078.x. [DOI] [PubMed] [Google Scholar]
  • 8.Headache Classification Committee of The International Headache Society The International Classification of Headache Disorders (2nd edit) Cephalalgia. 2004;24:1–160. [Google Scholar]
  • 9.Olesen J, Tfelt-Hansen P, Ramadan N, Goadsby PJ, Welch KMA. The Headaches. Philadelphia: Lippincott, Williams & Wilkins; 2005. [Google Scholar]
  • 10.Bertin L, Brion N, Farkkila M, Gobel H, Wessely P. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract. 1999;53:593–598. [PubMed] [Google Scholar]
  • 11.Dahlof C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia. 2001;21(suppl 1):9–12. doi: 10.1046/0333102401021s0104. [DOI] [PubMed] [Google Scholar]
  • 12.Pierce M, Marbury T, O’Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache. 2009;49:817–825. doi: 10.1111/j.1526-4610.2009.01437.x. [DOI] [PubMed] [Google Scholar]
  • 13.Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache. 2009;49:1435–1444. doi: 10.1111/j.1526-4610.2009.01530.x. [DOI] [PubMed] [Google Scholar]
  • 14.Silberstein SD, Kori SH, Tepper SJ, et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Cephalalgia. 2009;29:12–12. [Google Scholar]
  • 15.Goadsby PJ. Emerging therapies for migraine. Nature Clin Pract Neurol. 2007;3:610–619. doi: 10.1038/ncpneuro0639. [DOI] [PubMed] [Google Scholar]
  • 16.Humphrey PPA, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann NY Acad Sci. 1990;600:587–598. doi: 10.1111/j.1749-6632.1990.tb16912.x. [DOI] [PubMed] [Google Scholar]
  • 17.Leysen JE, Gommeren W, Heylen L, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Da, human 5-hydroxytryptamine1Db, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996;50:1567–1580. [PubMed] [Google Scholar]
  • 18.Diener HC, Tfelt-Hansen P, e Beukelaar F, et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2001;21:672–679. doi: 10.1046/j.0333-1024.2001.00222.x. [DOI] [PubMed] [Google Scholar]
  • 19.Goadsby PJ, Classey JD. Evidence for 5-HT1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122:491–498. doi: 10.1016/S0306-4522(03)00570-0. [DOI] [PubMed] [Google Scholar]
  • 20.Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:1230–1234. doi: 10.1016/S0140-6736(01)06347-4. [DOI] [PubMed] [Google Scholar]
  • 21.Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthesis inhibition in migraine. Lancet. 1997;349:401–402. doi: 10.1016/S0140-6736(97)80021-9. [DOI] [PubMed] [Google Scholar]
  • 22.Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache. Lancet. 1999;353:287–289. doi: 10.1016/S0140-6736(98)01079-4. [DOI] [PubMed] [Google Scholar]
  • 23.Iversen H. Human migraine models. Cephalalgia. 2001;21:781–785. doi: 10.1046/j.1468-2982.2001.00250.x. [DOI] [PubMed] [Google Scholar]
  • 24.Hoye K, Laurijssens BE, Harnisch LO, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia. 2009;29:132–132. [Google Scholar]
  • 25.Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia. 2009;29:124–124. [Google Scholar]
  • 26.Medve RA, Andrews JS. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. Cephalalgia. 2009;29:126–126. [Google Scholar]
  • 27.Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187. doi: 10.1002/ana.410280213. [DOI] [PubMed] [Google Scholar]
  • 28.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56. doi: 10.1002/ana.410330109. [DOI] [PubMed] [Google Scholar]
  • 29.Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Brit J Pharmacol. 2000;129:420–423. doi: 10.1038/sj.bjp.0703110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry. 2006;45:1881–1887. doi: 10.1021/bi052044w. [DOI] [PubMed] [Google Scholar]
  • 31.Williams TM, Stump CA, Nguyen DN, et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett. 2006;16:2595–2598. doi: 10.1016/j.bmcl.2006.02.051. [DOI] [PubMed] [Google Scholar]
  • 32.Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110. doi: 10.1056/NEJMoa030505. [DOI] [PubMed] [Google Scholar]
  • 33.Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123. doi: 10.1016/S0140-6736(08)61626-8. [DOI] [PubMed] [Google Scholar]
  • 34.Zagami AS, Edvinsson L, Hoskin KL, Goadsby PJ. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia. 1995;15(suppl 14):109–109. [Google Scholar]
  • 35.Henrik S, Steffen B, Wienecke T, et al. PACAP38 induces migraine-like attacks and vasodilatation: a causative role in migraine pathogenesis? Brain. 2009;132:16–25. doi: 10.1093/brain/awn307. [DOI] [PubMed] [Google Scholar]
  • 36.Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia. 2007;28:226–236. doi: 10.1111/j.1468-2982.2007.01497.x. [DOI] [PubMed] [Google Scholar]
  • 37.Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168–1170. doi: 10.1111/j.1468-2982.2006.01173.x. [DOI] [PubMed] [Google Scholar]
  • 38.Goadsby PJ, Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache. 2008;48:799–804. doi: 10.1111/j.1526-4610.2008.01157.x. [DOI] [PubMed] [Google Scholar]
  • 39.Schulman EA, Lake AE, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache. 2008;48:778–782. doi: 10.1111/j.1526-4610.2008.01132.x. [DOI] [PubMed] [Google Scholar]
  • 40.Schulman EA, Lake AE, Goadsby PJ, et al. Defining refractory migraine: results of the RHSIS survey of American Headache Society members. Headache. 2009;49:509–518. doi: 10.1111/j.1526-4610.2009.01370.x. [DOI] [PubMed] [Google Scholar]
  • 41.Saper J, Goadsby PJ, Silberstein S, Dodick DW. Occipital nerve stimulation (ONS) for treatment of intractable chronic migraine (ICM): 3-month results from the ONSTIM feasibility study. Neurology. 2009;72:A252–A252. [Google Scholar]
  • 42.Lipton RB, Goadsby PJ, Cady RK, et al. PRISM study: occiptal nerve stimulation for treatment-refractory migraine. Cephalalgia. 2009;29:30–30. [Google Scholar]
  • 43.Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127:220–230. doi: 10.1093/brain/awh022. [DOI] [PubMed] [Google Scholar]
  • 44.Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of durai afferent input. Brain. 2002;125:1496–1509. doi: 10.1093/brain/awf166. [DOI] [PubMed] [Google Scholar]
  • 45.Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. Brain. 2003;126:1801–1813. doi: 10.1093/brain/awg190. [DOI] [PubMed] [Google Scholar]
  • 46.Bums B, Watkins L, Goadsby PJ. Successful treatment of medically intractable cluster headache using occipital nerve stimulation (ONS) Lancet. 2007;369:1099–1106. doi: 10.1016/S0140-6736(07)60328-6. [DOI] [PubMed] [Google Scholar]
  • 47.Burns B, Watkins L, Goadsby PJ. Treatment of hemicrania continua by occipital nerve stimulation using the novel bion device: long term follow up of six patients. Lancet Neurol. 2008;7:1001–1012. doi: 10.1016/S1474-4422(08)70217-5. [DOI] [PubMed] [Google Scholar]
  • 48.May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet. 1998;352:275–278. doi: 10.1016/S0140-6736(98)02470-2. [DOI] [PubMed] [Google Scholar]
  • 49.May A, Ashburner J, Buchel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nature Med. 1999;5:836–838. doi: 10.1038/10561. [DOI] [PubMed] [Google Scholar]
  • 50.Leone M, Franzini A, Bussone G. Stereotatic stimulation of the posterior hypothalamic gray matter in a patient with intractable cluster headache. New Engl J Med. 2001;345:1428–1429. doi: 10.1056/NEJM200111083451915. [DOI] [PubMed] [Google Scholar]
  • 51.Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9:373–380. doi: 10.1016/S1474-4422(10)70054-5. [DOI] [PubMed] [Google Scholar]
  • 52.Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117:199–210. doi: 10.1093/brain/117.1.199. [DOI] [PubMed] [Google Scholar]
  • 53.Holland PR, Schembri CT, Fredrick JP, Goadsby PJ. Transcranial magentic stimulation for the treatment of migraine aura. Neurology. 2009;72:A250–A250. [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES